)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Kane Biotech
Kane Biotech (KNE) investor relations material
Kane Biotech Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary23 Apr, 2026
Executive summary
Revenue for 2025 was $427,869, down significantly from $2,080,879 in 2024, mainly due to discontinued animal health contract manufacturing and a strategic shift to the revyve product line.
Gross profit for 2025 was $(640), impacted by one-time sales and cost of sales adjustments, compared to $872,096 in 2024.
Net loss from continuing operations for 2025 was $(2,721,239), an improvement from $(3,161,097) in 2024.
The company undertook significant restructuring in 2025, reducing operating expenses and focusing on commercializing revyve wound care products.
Financial highlights
Q4 2025 revenue was $(21,140) due to a revenue reversal, compared to $125,859 in Q4 2024.
Q4 2025 gross profit was $7,567, up from a gross loss of $(87,204) in Q4 2024.
Q4 2025 net loss was $(546,856), improved from $(1,082,935) in Q4 2024.
Cash at year-end 2025 was $901,698.
Outlook and guidance
2026 objectives include expanding the U.S. and Canadian distributor network, growing revyve sales, and continuing clinical case series.
Plans to establish a Clinical Advisory Board and resume pre-clinical work on DispersinB Hydrogel for surgical wounds.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kane Biotech
- Clinically proven biofilm disruption technology targets a $423M+ US wound care market in 2026.KNE
Investor presentation23 Mar 2026 - $10.4M STEM sale gain drove $9.2M net income, debt elimination, and future growth momentum.KNEQ2 202422 Jan 2026
- Record Q3 revenue and first Revive/revyve sales drive growth, with major deals and funding secured.KNEQ3 202412 Jan 2026
- 2025 targets include clinical trial launches, expanded distribution, and cash flow positivity.KNEInvestor Update9 Jan 2026
- Revenue dropped sharply in Q3 2025, but clinical and regulatory progress for revyve advanced.KNEQ3 202511 Dec 2025
- Revenue plunged post-animal health sale; net loss narrowed, with new board and US focus.KNEQ2 20259 Sep 2025
- Revenue surged and losses narrowed as restructuring and cost-saving measures took effect.KNEQ1 202516 Jun 2025
- Revenue surged and net loss narrowed as Kane Biotech pivots to revyve wound care and secures new funding.KNEQ4 20246 Jun 2025
Next Kane Biotech earnings date
Q1 202627 May, 2026
Kane Biotech
Next Kane Biotech earnings date
Q1 202627 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage